Trial Profile
A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Iscalimab (Primary) ; Iscalimab (Primary) ; Corticosteroids; Mycophenolate mofetil; Mycophenolate mofetil; Prednisolone; Tacrolimus; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms CIRRUS I
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Mar 2022 This trial has been discontinued in Italy (End Date: 29 Oct 2021), according to European Clinical Trials Database record.
- 12 Jan 2022 Status changed from active, no longer recruiting to completed.
- 04 Dec 2021 This trial has been completed in Sweden, according to European Clinical Trials Database record.